康華生物(300841.SZ):子公司簽下杭州佑本寵物產品寵物狂犬病滅活疫苗中國全渠道總經銷商
格隆匯9月22日丨康華生物(300841.SZ)公佈,公司全資子公司康華動保(成都)生物科技有限公司(簡稱“康華動保”)與杭州佑本動物疫苗有限公司(簡稱“杭州佑本”)於近日簽訂了《康華動保寵物狂犬病滅活疫苗總經銷代理協議》,杭州佑本授權康華動保為杭州佑本寵物產品寵物狂犬病滅活疫苗在中國大陸及澳門、香港和台灣地區政府採購和寵物醫院線上線下全渠道的總經銷商。經銷代理期限為第一階段:2021年11月1日-2026年12月31日;第二階段:2027年1月1日-2032年12月31日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.